As FDA raises bar in rare diseases, pivotal moment nears for RegenxBio

This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

I was enjoying the relatively balmy SF weather. Alas, back to Boston winter. Only 10 more(ish) weeks to go! 

The FDA raises the bar in rare diseases

I want to return to the conversation I had at our JPM Week live event with biotech investors Rod Wong and Agustin Mohedas. You will not be surprised to learn that the Food and Drug Administration and its impact on biotech came up. 

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In